Over the last fifteen years, the medical treatment of metastatic renal cell carcinoma (RCC) has been revolutionized with the introduction of highly effective targeted therapies with multi-tyrosine kinase and mTor inhibitors, and monoclonal antibodies like angiogenesis and immune checkpoint inhibitors [154,169,203,204,205,206,214,215,216]. The gene discussed is MTOR; the disease is renal cell carcinoma.